"I don't think I'm humouring him B2. I think he's genuinely confused and way out of his depth in business. I'm happy to help fellow investors learn and understand things but Huey took it a little too far. Point taken though."
Was it ever about Lab21?
Got the the impression it was more about having a childish pop at me.
And now you're left looking very childish. Because...............
https://www.micheldyens.com/selected-transactions/lab21-has-acquired-novacyt-novacyt-was-advised-by-michel-dyens-co
"Lab21 has acquired Novacyt. Novacyt was advised by Michel Dyens & Co.
Novacyt (NYSE-ALTERNEXT: ALNOV), is a leading diagnostics manufacturer that develops and markets innovative solutions in liquid-based cytology for the detection of cancer, including cervical cancer and other non-gynaecological cancers, and Lab21 is a UK-based global specialist in personalized medicine and clinical diagnostics.
The combined group will create an emerging diagnostics leader with a portfolio of cancer and infectious diseases diagnostic products and services.
Michel Dyens & Co was the exclusive financial advisor of Novacyt’s shareholders on their M&A strategy, and ultimately the stock-for-stock transaction with Lab21."
Michel Dyens & Co is not a blogger
Stop being a child in trying to bully others off this bb, you haven't got the skills for it. take this as a lesson and grow up.
You're the only person that believes that Michel Dyens & Co is some bloke called Michel and their client list is an article written by this Michel person.
The rest of the world says
So..........
https://www.micheldyens.com/selected-transactions/lab21-has-acquired-novacyt-novacyt-was-advised-by-michel-dyens-co
"Lab21 has acquired Novacyt. Novacyt was advised by Michel Dyens & Co.
Novacyt (NYSE-ALTERNEXT: ALNOV), is a leading diagnostics manufacturer that develops and markets innovative solutions in liquid-based cytology for the detection of cancer, including cervical cancer and other non-gynaecological cancers, and Lab21 is a UK-based global specialist in personalized medicine and clinical diagnostics.
The combined group will create an emerging diagnostics leader with a portfolio of cancer and infectious diseases diagnostic products and services.
Michel Dyens & Co was the exclusive financial advisor of Novacyt’s shareholders on their M&A strategy, and ultimately the stock-for-stock transaction with Lab21."
Why do you think it's a blogger called Michel.
"I did see that article from Michel. Not sure why he would refer to it as Lab21 acquired Novacyt."
You really think that the client list for Michel Dyens & Co, a global investment banking firm is really an article written by some bloke called Michel
https://www.micheldyens.com/selected-transactions/lab21-has-acquired-novacyt-novacyt-was-advised-by-michel-dyens-co
So..........
https://www.micheldyens.com/selected-transactions/lab21-has-acquired-novacyt-novacyt-was-advised-by-michel-dyens-co
"Lab21 has acquired Novacyt. Novacyt was advised by Michel Dyens & Co.
Novacyt (NYSE-ALTERNEXT: ALNOV), is a leading diagnostics manufacturer that develops and markets innovative solutions in liquid-based cytology for the detection of cancer, including cervical cancer and other non-gynaecological cancers, and Lab21 is a UK-based global specialist in personalized medicine and clinical diagnostics.
The combined group will create an emerging diagnostics leader with a portfolio of cancer and infectious diseases diagnostic products and services.
Michel Dyens & Co was the exclusive financial advisor of Novacyt’s shareholders on their M&A strategy, and ultimately the stock-for-stock transaction with Lab21."
That is Novacyt's financial advisor for the deal. That is taken from their client list.
But you are insisting that Michel Dyens & Co is actually some bloke called Michel and their client list is an article written by this Michel person. Yes?
You don't understand what you read because you don't understand what a reverse takeover is.
You keep posting stuff concerning the takeover but don't understand the 'reverse'.
You even post "In July 2014, Lab21 became part of the Group via a reverse merger with Novacyt." and then deny it. Loony.
Read what you post
"During 2014, Lab21 saw the opportunity to merge with a publicly listed, high technology diagnostics
business, which also provided it with access to new proprietary products and new sources of
capital."
Lab21 initiated the takeover. They went to Novacyt with a proposal (no shares purchased, that was more of your BS) Novacyt Shareholders approved takeover "Accordingly, Lab21 was acquired". Novacyt CEO steps down. Lab21 become the new management " The management of Lab21 was appointed to run the
combined business " thats the all important control. And Novacyt and the BoD was restructured "to reflect a largely UK domiciled business" what would be following Lab21's strategy.
Notice how everything happens in reverse from an ordinary takeover. That's why it's called a reverse takeover.
You're posting all this, you keep posting stuff that agrees with it been a reverse takeover
You even deny this is true you pretend it's some bloke called Michel and not a global investment banking firm who managed the deal for Novacyt.
Here's Novacyt's financial advisors for the takeover,
https://www.micheldyens.com/selected-transactions/lab21-has-acquired-novacyt-novacyt-was-advised-by-michel-dyens-co
"Lab21 has acquired Novacyt. Novacyt was advised by Michel Dyens & Co.
Novacyt (NYSE-ALTERNEXT: ALNOV), is a leading diagnostics manufacturer that develops and markets innovative solutions in liquid-based cytology for the detection of cancer, including cervical cancer and other non-gynaecological cancers, and Lab21 is a UK-based global specialist in personalized medicine and clinical diagnostics.
The combined group will create an emerging diagnostics leader with a portfolio of cancer and infectious diseases diagnostic products and services.
Michel Dyens & Co was the exclusive financial advisor of Novacyt’s shareholders on their M&A strategy, and ultimately the stock-for-stock transaction with Lab21."
That is Novacyt's financial advisor for the deal.
"I did see that article from Michel. Not sure why he would refer to it as Lab21 acquired Novacyt."
Michel Dyens & Co is an investment banking firm with a couple of hundred employees HQs in Paris and New York, not a bloke named Michel
You don't understand 'reverse takeover' so you don't understand the RNSs or accounts
Same goes for the AIM doc, it says 'reverse merger' but you don't understand the meaning.
Your left with a bunch of online articles, but other articles state it as a Lab21 takeover.
I had hoped just 4 words from a global investment banking firm who were the Novacyt financial advisors on the deal would get through.
"Lab21 has acquired Novacyt. Novacyt was advised by Michel Dyens & Co."
here's that link again
https://www.micheldyens.com/selected-transactions/lab21-has-acquired-novacyt-novacyt-was-advised-by-michel-dyens-co
Look it's even in the URL. Go on try again "Lab21 has acquired Novacyt"
Still not understanding what you read. OK try the link to Novacyt's financial advisors for the deal, all you need to do is understand the words in the headline.
"Lab21 has acquired Novacyt. Novacyt was advised by Michel Dyens & Co."
here's that link again
https://www.micheldyens.com/selected-transactions/lab21-has-acquired-novacyt-novacyt-was-advised-by-michel-dyens-co
Look it's even in the URL.
Here's Novacyt's financial advisors for the takeover,
https://www.micheldyens.com/selected-transactions/lab21-has-acquired-novacyt-novacyt-was-advised-by-michel-dyens-co
"Lab21 has acquired Novacyt. Novacyt was advised by Michel Dyens & Co.
Novacyt (NYSE-ALTERNEXT: ALNOV), is a leading diagnostics manufacturer that develops and markets innovative solutions in liquid-based cytology for the detection of cancer, including cervical cancer and other non-gynaecological cancers, and Lab21 is a UK-based global specialist in personalized medicine and clinical diagnostics.
The combined group will create an emerging diagnostics leader with a portfolio of cancer and infectious diseases diagnostic products and services.
Michel Dyens & Co was the exclusive financial advisor of Novacyt’s shareholders on their M&A strategy, and ultimately the stock-for-stock transaction with Lab21."
That is Novacyt's financial advisor for the deal, understand.
No, no humour me DRB, have a read
https://novacyt.com/wp-content/uploads/2022/05/Admission-Document-Novacyt-18-October-2017.pdf
"Novacyt has a successful track record of undertaking acquisitions, including that of Lab21 (through
a reverse merger) in July 2014 ....."
that's their admission doc for an AIM listing, page 13 (unlucky for some)
Please tell me you understand now or will you continue to be so very childish
Though you had grasped the understanding of 'control' but you haven't. Just another word. Struggling with 'reverse' too.
And you can't decide if it was merger or takeover because you are just looking at words.
Have you grasped that Lab21 was an investment vehicle yet. Bought several Co.s before taking over Novacyt.
Did you understand that a new Novacyt entity was created with new CEO and new shares.
Have you understood anything
Round of applause there DRB, you are 100% correct (I know you love a big %) I'd go further as would any business person and say if you control something you effectively own it. So to takeover is to take control, to take control is to have effective ownership.
You don't need to own any shares to takeover a Plc, you need to make an offer to the BoD which returns value to the shareholders, the BoD is legally obliged to offer it to SH, shareholders get to vote yes or no.
No, Novacyt didn't give shares to Lab21 because when the Novacyt SH voted to be taken over, that Novacyt stopped existing and a new Novacyt legal entity was created and the CEO of the new entity (guess who) divvied out the new shares in the new Novacyt to everyone as per their entitlement ( OK Mullis was legally obliged to issue the shares, but still it was the Lab21 (ex)CEO who signed off on it. Crazy stuff I know)
OK on to explaining control and ownership, a Plc is owned by it's SH and run by the BoD. So Lab21 is CEO, that's control of the day to day business. What about SH control. Because you're not understanding what you read you only see numbers. Ok SH in old Novacyt got a bigger slice of the new company than Lab21 SH. But there are 000's of Novacyt SH and only a few Lab21 SH. All SH are individual owners of a piece of Novacyt, Lab21 SH got much bigger slices of a smaller portion than the slivers dished out from the bigger portion to old Novacyt SH. So Lab21 SH would have controlled any SH votes.
So, there you go, Lab21 had control of day to day business and (ex)Lab21 SH could exercise SH control.
"They can't seem to decide whether it's a Novacyt acquisition or a merger but one thing for sure is it's not a Lab21 acquisition."
Apart from the childish rationale that names matter, why are you so sure that the Venture Capital Vehicle Lab21 didn't takeover the manufacturer Novacyt.
You just keep reposting the same stuff hoping reality changes. It doesn't Lab21 did a reverse takeover of Novacyt.
Don't ya think it's funny Novacyt raising 3mm in funding after spending 40mm on Lab21.
Naw course ye don't cos you don't understand what you are reading.
You said Novacyt took over Lab21, you posted an article saying the transaction cost 40mm, therefore you say Novacyt paid 40mm for Lab21. What part are you disputing now, or tell me how much did Novacyt pay than (in your wee world)
Oh stop , you're slaying me with this googling onslaught, shame you still don't understand what you're reading, but liking the new prose still to add some drama,
Throwing %'s out there is also childish, in business it's about return on investment, not my share is bigger than your share. Although if Lab21 shareholders (incidentally who were they) had wanted a deal where they ended up with the bigger share they'd have probably bought a smaller company. Although the money would still haver been the same. But, they'd have had the bigger share %. Very important having a bigger % in business, oh yes indeed. Child.
Here, now you know a little about Lab21, tell me, what exactly did the moneymen give their backing too. Seems a bit strange to backing a company to be taken over when you invested in the company to take other companies over, unless.......
This is what what it's like to be savaged by a dead sheep
I'm not basing anything on anything. It's a fact. Why are you so hung up on names, it's childish, no-one in business cares about company names, companies are business vehicles not children. Lab21 prior to taking over Novacyt was a venture capital vehicle, it had raised about £15mm and bought several companies who continued under their own brands, Lab21 as a brand didn't really exist, why, because it was a vc shell. Novacyt as well as a big buy, also gave it an immediate stock market listing. No-0ne worries about the name of the company, they worry about business.
This is such a childish conversation.
I can't be bothered, this is idiotic.
Simple question, why was the takeover subject to a Novacyt shareholder vote and not a Lab21 shareholder vote.
Answer, because your shareholders have a vote on been taken over, shareholders do not vote on acquiring.
Next little nugget, you say Novacyt paid 40mm for Lab21. Really, Lab21 worth 40mm in 2014. Today you say it's shutting because it's loss making. So you never thought (as you read) Lab 21 can't be worth 40mm, or if you thought it was, are you not surprised it's losing money a few years later.
Seriously you just read stuff with no idea of what it actually means.